Ironwood Pharmaceuticals Inc
SWB:I76
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Ironwood Pharmaceuticals Inc
SWB:I76
|
US |
|
A
|
Aeris Resources Ltd
OTC:ARSRF
|
AU |
|
K
|
Kulicke and Soffa Industries Inc
XMUN:KU1
|
SG |
|
Nova Pacific Metals Corp
F:YQ10
|
CA |
|
Orthex Oyj
F:4QU
|
FI |
|
Y
|
Yamazaki Co Ltd
TSE:6147
|
JP |
|
Mitsui E&S Holdings Co Ltd
TSE:7003
|
JP |
|
P
|
Precicion Trim Inc
OTC:PRTR
|
CN |
Intrinsic Value
Is I76 undervalued or overvalued?
See the intrinsic value estimate for 
Ironwood Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
I76 looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with I76’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Ironwood Pharmaceuticals Does
Ironwood Pharmaceuticals is a biopharmaceutical company focused on medicines for gastrointestinal, or digestive, disorders. Its main product is Linzess, a prescription drug used for conditions such as irritable bowel syndrome with constipation and chronic idiopathic constipation. The company also works on other gut-related drug programs, but its business is still centered on treating chronic digestive diseases.
- Headquarters
- United States of America US
- Employees
- 100
- IPO date
- Feb 3, 2010
Ironwood Pharmaceuticals has no economic moat
Ironwood Pharmaceuticals Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysisLatest Earnings Call
- EPS
- $0.31
- Expected
- $0.26
- Surprise
- +19.2%
- Stock, day of the call
- +3.4%
Revenue & Expenses Breakdown
Ironwood Pharmaceuticals Inc
Earnings Waterfall
Ironwood Pharmaceuticals Inc
The intrinsic value for Ironwood Pharmaceuticals Inc (I76) under the Base Case is hidden EUR.
Compared with the current market price of 3.66 EUR, the stock appears hidden.